Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Alzheimer Disease · Major Depressive Disorder · CGTX

Cognition Therapeutics

COGNITION THERAPEUTICS INC

Cognition Therapeutics patent portfolio — 12 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
2500 Westchester Ave, Purchase, New York 10577, US HQ
2007 Founded
32 Employees
Public company Type
CGTX · NYSE Ticker
Company details
Status
Public
HQ
2500 Westchester Ave, Purchase, New York 10577, US
Founded
2007
Employees
32
Programs
33
Drugs
26
Patents
12
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Cognition Therapeutics patents

12 pharmaceutical patents indexed for Cognition Therapeutics. 1 expire within 24 months.

Cognition Therapeutics has 12 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

12 patents

Patent portfolio

  1. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12157743

    Solid forms of Alpha-1062 gluconate

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11795176

    Solid forms of Alpha-1062 gluconate

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11123351

    Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10603326

    Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10351589

    3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10342804

    Steroid compound for use in the treatment of hepatic encephalopathy

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10278977

    Methods for treating hypersomnolence

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9801894

    Steroid compound for use in the treatment of hepatic encephalopathy

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9200028

    Steroids having increased water solubility and resistance against metabolism and methods for their production

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7619005

    Methods for treating cognitive impairment in humans with Multiple Sclerosis

    Expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7244769

    Methods for treating an impairment in memory consolidation

    Expires Mon Jul 12 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Cognition Therapeutics have?

12 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Cognition Therapeutics patents expire?

1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.